AstraZeneca Invests $2 Billion in Summit Therapeutics to Pair Its ADCs With Ivonescimab

AstraZeneca will invest $2 billion in Summit Therapeutics and launch a clinical collaboration built around Summit's experimental cancer drug ivonescimab, a sizeable strategic bet on one of the most closely watched new classes of cancer drugs.

Under the agreement, announced late on 28 September and in financial markets on 29 September 2026, AstraZeneca will buy about 109,000 shares of newly issued preferred stock in Summit, convertible into common stock at a ratio of 1:1,000. Once the investment closes, AstraZeneca will hold rights equivalent to about 12% of Summit's outstanding common stock, or about 10.6% on a fully diluted basis. The investment implies a conversion price of about $18.36 per share and is expected to close within a week.

Summit's shares rose about 23% in premarket trading in New York on Tuesday, according to Reuters. AstraZeneca's London-listed shares climbed about 1.6% to a two-month high.

The science at the centre

Ivonescimab is an investigational bispecific antibody that combines two established approaches to cancer treatment in a single molecule. It blocks PD-1, a checkpoint protein that tumours exploit to evade the immune system, and it inhibits VEGF, a growth factor that tumours use to build blood vessels. By targeting both pathways, the drug aims to combine the benefits of immunotherapy with anti-angiogenic effects.

The molecule was originally developed by China's Akeso, which licensed rights in major markets including the United States, Europe and Japan to Summit in 2022. Clinical data from trials in China, including a head-to-head study against Merck's blockbuster immunotherapy Keytruda in certain lung cancer patients, drew intense industry attention and helped spark a wave of interest in PD-1/VEGF bispecifics among large drugmakers.

According to Summit, ivonescimab is under regulatory review in the United States, with a target action date in November 2026. A positive decision would represent a major milestone for the company and for the new class of drugs.

What the collaboration involves

The companies will first test ivonescimab in combination with sonesitatug vedotin, known as Sone-Ve, an AstraZeneca antibody-drug conjugate that targets Claudin 18.2, a protein found in the stomach lining and a validated target in gastrointestinal cancers. Antibody-drug conjugates, or ADCs, deliver potent chemotherapy directly to tumour cells, reducing damage to healthy tissue.

The initial focus is on gastrointestinal cancers, including gastric cancer, gastroesophageal junction cancer and oesophageal adenocarcinoma. The partners plan to expand evaluation of ivonescimab with a broader set of AstraZeneca cancer medicines, including other ADCs, with AstraZeneca sponsoring studies.

Importantly, each company will retain development and commercial rights to its own molecules. The structure allows AstraZeneca to gain exposure to ivonescimab's potential and to test it with its own portfolio, without acquiring Summit outright.

Why AstraZeneca chose an equity stake

The deal structure reflects AstraZeneca's strategic priorities. Under chief executive Pascal Soriot, the company has built one of the industry's strongest oncology franchises, with a particular focus on ADCs and immuno-oncology combinations. Combining ADCs with immunotherapy is widely seen as one of the most promising directions in cancer treatment, and a PD-1/VEGF bispecific offers a potentially differentiated partner for its ADC pipeline.

"AstraZeneca is investing $2 billion in Summit to accelerate development of ivonescimab combinations with our cancer medicines, including our ADC portfolio," the company said. It added that the investment provides exposure to Summit's future growth, while combining an equity investment with a clinical collaboration aligns both companies while preserving their independence.

An equity stake rather than a full acquisition limits AstraZeneca's financial exposure while ivonescimab's US regulatory outcome and broader clinical data remain pending. It also keeps options open. Should the drug succeed, a 12% shareholder with a close clinical partnership would be well placed in any future discussions about a deeper relationship.

A validation for Summit

For Summit, the investment is transformative. The $2 billion represents roughly 14% of the company's market capitalisation, according to analysts, and significantly extends its cash runway for an extensive Phase III programme. Late-stage oncology trials are expensive and can take years, and the capital allows Summit to pursue multiple indications at once.

"This significant investment, as well as the collaboration, is a powerful validation of the potential of ivonescimab," said Robert Duggan, Summit's chairman and co-chief executive. President and co-chief executive Maky Zanganeh said a growing body of evidence supports the drug's differentiated PD-1/VEGF bispecific approach.

Evercore ISI analyst Cory Kasimov described the investment as a validating buy-in for Summit from a global leader in cancer treatment, offering a much-needed cash infusion while preserving the company's strategic options, according to Reuters.
## What investors will watch

Several milestones will shape how the deal is judged. The first is the US regulatory decision on ivonescimab, expected in November. Approval would give Summit its first commercial product in the United States and provide a foundation for combination strategies. A delay or rejection would raise questions about the timeline for the broader programme, although the AstraZeneca collaboration would continue.

The second is the design and pace of the combination trials. Investors will look for details on the patient populations, endpoints and expected timelines for data readouts in gastrointestinal cancers, and for signs of how quickly the partnership expands into other tumour types.

The third is how Summit deploys its strengthened balance sheet. With significantly more capital, the company can accelerate trials, build commercial infrastructure ahead of a potential launch and pursue additional indications. How it balances speed with capital discipline will influence its valuation in the months ahead.

The race in PD-1/VEGF bispecifics

The deal underscores the intensity of competition in PD-1/VEGF bispecifics. Several large pharmaceutical companies have struck licensing deals with Chinese biotechs developing similar molecules, reflecting both the promise of the class and China's growing role as a source of innovative drug candidates. The field is now crowded, and the eventual winners will be determined by clinical data across multiple tumour types and by the ability to combine these drugs effectively with other treatments.

The investment also fits a broader pattern of dealmaking in 2026, as large drugmakers seek to replenish pipelines ahead of patent expiries on major products later this decade. Around the same time, Novo Nordisk agreed to pay up to $2.6 billion to China's Hengrui for rights to a weight-loss pill, another sign of how global pharma is sourcing innovation.

For patients with gastrointestinal cancers, many of whom have limited treatment options and poor survival rates, the collaboration offers hope of new combinations that could improve outcomes. For investors, the coming months will be critical: the US regulatory decision on ivonescimab in November, and early data from combination studies, will determine whether AstraZeneca's $2 billion bet proves to be one of the shrewdest moves in oncology this year.